Vysis PathVysion Cleared For Herceptin Labeling; Is Early Detection Next?
This article was originally published in The Gray Sheet
Executive Summary
Genentech's Herceptin revised labeling allows use of Abbott/Vysis' PathVysion FISH assay to select drug treatment, but declines to support the assay's utility for the general population